Your Cart Is Empty!
The development of novel platforms to assess the presence of circulating nucleic acids is challenging due to their low abundance in human fluids and the difficulty in obtaining a sustainable source of patient-relevant material. Translating the potential of circulating nucleic acids detection into the clinic requires highly precise and accurate technologies to enable sensitive and specific measurements.
Utilising proprietary genome editing technology, Horizon’s diagnostics division has established a range of best-in-class, genetically defined genomic reference standards, including FFPE sections and purified DNA. These standards offer a sustainable and highly defined source of reference material to laboratories, proficiency schemes and technology developers. Here we present the design and validation of fit-for-purpose Cell Free DNA Reference Standards to evaluate the analytical performance of cell free DNA assays for circulating tumor DNA and solid organ transplantation. Using our highly validated isogenic cell lines, a panel of Cell Free DNA Reference Standards were developed. These genetically defined standards are fragmented to the approximate size of circulating DNA extracted from plasma. Using Digital PCR for absolute quantification of mutant and wild type variants, we were able to show the creation of extremely accurate reference material even at allelic frequencies down to 0.1% across a range of markers.
As part of the early access program, Horizon Diagnostics is proud to announce the release of two new products.
The Structural Multiplex Reference Standard and Tru-Q 0 Reference Standard are two products which allow for..
Highly defined standards that you can use for validation and optimization
This highly defined reference standard contains 8 eight engineered mutations, 3 three endogenous mutations and 500 tertiary mutations each calibrated by digital PCR to a chosen allelic frequency ranging between 0.8% and 24%.
Brisbane, CA, USA and Cambridge, UK, 3rd June 2015: CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, diagnostic surveillance solutions for transplant recipients and Horizon Discovery Group plc (Horizon), an international life science company supplyingreagent tools and services that power genomics research and the development of personalized medicines, today announced they have entered into a collaboration to develop cell-free DNA (cfDNA) reference standards. These HDx™ Reference standards, being developed by HorizonDiagnostics, a division of Horizon, will support proficiency testing of CareDx’s solid organ transplant injury monitoring diagnostic tests and will be integrated into CLIA laboratory testing.
CIQC Annual Symposium
Event: American Society of Clinical Oncology Meeting 2015
Horizon’s diagnostics division provides consistent and reproducible reference standards for IHC assays
Cambridge, UK, 06 May 2015: Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, today announced it has introduced a unique range of genetically defined, highly characterized HDx Reference Standards for Immunohistochemistry (IHC) assays. The product range has been developed by Horizon’s diagnostics division.
Register for a free pack of IHC HDx Reference Standards Targets covered in the offer: ALK, MET, ROS1, BRAF V600E and EGFR Valid until May 30th 2015 Benefit from using our IHC HDx Reference Standards as your on-slide control. Recommend us to colleagues and friends and they get a 20% discount.
Horizon to provide human genomic reference standards to assure quality and performance of Transgenomic’s Multiplexed ICE COLD-PCR kits
CAMBRIDGE, UK, and OMAHA, NE, USA (April, 23, 2015)Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, and Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology and inherited diseases through advanced diagnostic tests and clinical and research services, today announced a new Original Equipment Manufacture (OEM) agreement to incorporate Horizon’s human genomic reference standards, produced by Horizon’s Diagnostics division, into Transgenomic’s Multiplexed ICE COLD-PCRTM (MX-ICP) kits for use in research and clinical applications. Further details of the agreement were not disclosed.
Why should laboratories be using Genomic DNA rather than Plasmids and what are the advantages?
In molecular biology, plasmid DNA has proved to be a vital tool for many applications. However, when developing or validating assays which will ultimately measure human genomic DNA samples, plasmid DNA may not be an ideal control sample.
1-10 of 25
Send us a message
See our ordering page
Click here to register with us
Find out here